Baseline T Classification Predicts Early Tumor Regrowth After Nonoperative Management in Distal Rectal Cancer After Extended Neoadjuvant Chemoradiation and Initial Complete Clinical Response

Imagem de Miniatura
Arquivos
art_HABR-GAMA_Baseline_T_Classification_Predicts_Early_Tumor_Regrowth_After_2017.PDF (494.94 KB)
Citações na Scopus
63
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
JULIAO, Guilherme Pagin Sao
VAILATI, Bruna Borba
FERNANDEZ, Laura Melina
Citação
DISEASES OF THE COLON & RECTUM, v.60, n.6, p.586-594, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND: Selected patients with rectal cancer and complete clinical response after neoadjuvant chemoradiation have been managed nonoperatively with acceptable outcomes. However, approximate to 20% of these patients will develop early tumor regrowth. Identification of these patients could select candidates for more intensive follow-up. OBJECTIVE: The purpose of this study was to investigate the influence of baseline radiological T classification on recurrences after a complete clinical response managed nonoperatively after chemoradiation. DESIGN: This was a retrospective review of a prospective collected database. SETTINGS: The study was conducted at a single center. PATIENTS: Patients with distal rectal cancer (cT2-4N0-2M0) undergoing extended chemoradiation (54 Gy + 5-fluorouracil-based chemotherapy) were eligible. Patients were reassessed for tumor response at 10 weeks after radiation completion. Patients with complete clinical response (clinical, radiological, and endoscopic) were managed nonoperatively and strictly followed. MAIN OUTCOMES MEASURES: Complete clinical response rates, early tumor regrowth rates (<12 mo), local recurrence-free survival, and distant metastases-free survival were measured. RESULTS: A total of 91 consecutive patients with rectal cancer underwent extended chemoradiation. Sixty-one patients developed initial complete clinical response (67%). cT2 patients developed similar initial complete clinical response rates compared with cT3/T4 (72% vs 63%; p = 0.403). Early tumor regrowths were more frequent among baseline cT3/4 when compared with cT2 patients (30% vs 3%; p = 0.007). There were no differences in late local recurrences (p = 0.593) or systemic recurrences (p = 0.387). Local recurrence-free survival was significantly better for cT2 patients at 1 year (96% vs 69%; p = 0.009). After Cox regression analysis, baseline T stage was an independent predictor of improved local recurrence-free survival at 1 year (p = 0.03; OR = 0.09 (95% CI, 0.01-0.81)). LIMITATIONS: This study was limited by its small sample size, retrospective nature, and short follow-up. CONCLUSIONS: cT2 patients who develop complete clinical response after extended chemoradiation managed nonoperatively are less likely to develop early tumor regrowths when compared with cT3/4 patients. cT3/4 patients should undergo more intensive follow-up after a complete clinical response to allow for early detection of early regrowths.
Palavras-chave
Chemoradiation, Complete clinical response, Rectal cancer, Watch and wait
URI
https://observatorio.fm.usp.br/handle/OPI/21904
Referências
  1. Appelt AL, 2015, LANCET ONCOL, V16, P919, DOI 10.1016/S1470-2045(15)00120-5
  2. Beets-Tan RGH, 2001, LANCET, V357, P497, DOI 10.1016/S0140-6736(00)04040-X
  3. Bettoni F, 2017, ANN SURG, V265, pE4, DOI 10.1097/SLA.0000000000001937
  4. Duldulao MP, 2013, DIS COLON RECTUM, V56, P142, DOI 10.1097/DCR.0b013e31827541e2
  5. Garcia-Aguilar J, 2012, ANN SURG ONCOL, V19, P384, DOI 10.1245/s10434-011-1933-7
  6. Gerard JP, 2004, J CLIN ONCOL, V22, P2404, DOI 10.1200/JCO.2004.08.170
  7. Habr-Gama A, 1998, DIS COLON RECTUM, V41, P1087, DOI 10.1007/BF02239429
  8. Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32
  9. Habr-Gama A, 2009, BRIT J SURG, V96, P125, DOI 10.1002/bjs.6470
  10. Habr-Gama A, 2008, INT J RADIAT ONCOL, V71, P1181, DOI 10.1016/j.ijrobp.2007.11.035
  11. Habr-Gama A, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0598-6
  12. Habr-Gama A, 2014, INT J RADIAT ONCOL, V88, P822, DOI 10.1016/j.ijrobp.2013.12.012
  13. Habr-Gama A, 2013, DIS COLON RECTUM, V56, P1109, DOI 10.1097/DCR.0b013e3182a25c4e
  14. Habr-Gama A, 2010, DIS COLON RECTUM, V53, P1692, DOI 10.1007/DCR.0b013e3181f42b89
  15. Maas M, 2011, J CLIN ONCOL, V29, P4633, DOI 10.1200/JCO.2011.37.7176
  16. Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8
  17. Patel UB, 2012, ANN SURG ONCOL, V19, P2842, DOI 10.1245/s10434-012-2309-3
  18. Perez RO, 2014, TECH COLOPROCTOL, V18, P699, DOI 10.1007/s10151-013-1113-9
  19. Perez RO, 2016, DIS COLON RECTUM, V59, P895, DOI 10.1097/DCR.0000000000000620
  20. Sanghera P, 2008, CLIN ONCOL-UK, V20, P176, DOI 10.1016/j.clon.2007.11.013
  21. Smith FM, 2015, DIS COLON RECTUM, V58, P159, DOI 10.1097/DCR.0000000000000281
  22. Smith JD, 2012, ANN SURG, V256, P965, DOI 10.1097/SLA.0b013e3182759f1c

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/35
Artigos e Materiais de Revistas Científicas - ODS/03